Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Raghu, G. et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur. Respir. J. 48, 179–186 (2016).
Raghu, G. et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 192, e3–e19 (2015).
Skandamis, A. et al. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. J. Drug Assess. 8, 55–61 (2019).
Speca S. et al. Novel PPARγ modulator GED-0507-34 levo ameliorates inflammation-driven intestinal fibrosis. Inflamm. Bowel Dis. 22, 279–292 (2016).
Spagnolo, P. & Cottin, V. Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. J. Med. Genet. 54, 93–99 (2017).
Pirat, C. et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J. Med. Chem. 55, 4027–4061 (2012).
Fumery, M. et al. Peroxisome proliferator-activated receptor gamma (PPARγ) regulates lactase expression and activity in the gut. EMBO Mol. Med. 9, 1471–1481 (2017).
Rousseaux, C. et al. Preclinical evaluation of intestinal anti-inflammatory/analgesic properties and phase I clinical trial of a new PPAR Agonist Ged-0507-34-Levo. Gastroenterology 140, S-515 (2011).
Di Gregorio, J. et al. Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis. PLoS ONE 12, e0171093 (2017).
Ashcroft, T. et al. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41, 467–470 (1988).
We thank Nogra Pharma Ltd., Dublin, Ireland, for partly funding this study. Nogra Pharma Ltd. has filed a patent for the use of GED-0507 in inflammatory/fibrotic diseases.
P.D. reports personal fees from PPM Services, during the conduct of the study; personal fees from Ferring, Switzerland; personal fees from Intralytix, USA; personal fees from Lesaffre, France; personal fees from KitoZyme, Belgium; personal fees from Abbott, France; personal fees from Janssen, France; personal fees from MSD, France; personal fees from Norgine, France; personal fees from Pfizer, France; personal fees from Takeda, France, outside the submitted work. P.S. reports personal fees from PPM Services during the conduct of the study; grants, personal fees and non-financial support from Roche; grants and non-financial support from PPM Services; grants, personal fees and non-financial support from Boehringer-Ingelheim; personal fees from RedX Pharma; personal fees from Galapagos; personal fees from Chiesi, outside the submitted work. S.S., C.D., C.R., and P.C. have nothing to disclose.
About this article
Cite this article
Speca, S., Dubuquoy, C., Rousseaux, C. et al. GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. Cell Mol Immunol 17, 1272–1274 (2020). https://doi.org/10.1038/s41423-020-0394-y
Frontiers in Cell and Developmental Biology (2020)